Starting Thursday, the FDA's Pharmacy Compounding Advisory Committee holds a two-day vote at its Maryland campus on whether seven peptides — including BPC-157 and TB-500 — should be available from licensed compounding pharmacies with a doctor's prescription. Vendors already sell these compounds online under "for research use only" labels, with no sterility guarantees and no dosing oversight. The FDA's own staff briefing documents recommend against adding any of the seven. The hearing exists because the Alliance for Pharmacy Compounding reached a 2024 legal settlement that forced FDA to submit these compounds to formal public review — after FDA had restricted them in 2023 without following required notice-and-comment rulemaking.

1. No Human Evidence, No Approval (FDA Scientists, 2024 Panel)

The FDA's own scientists say the evidence bar isn't close to cleared.

There's almost no human data on these compounds. BPC-157 has more than 100 animal studies but only three published human studies, none with a proper control group. A December 2025 scoping review found every published BPC-157 study reports positive effects — scientists call that a publication bias red flag, not reassurance.

The 2024 advisory committee agreed overwhelmingly. When the PCAC reviewed previous batches of peptides, it voted against all of them: 11 yes-votes versus 167 no-votes across those substantive reviews.

The FDA's scientists have flagged specific safety risks. Dr. Marianne San Antonio of the FDA's Pharmacy Compounding Review Team raised concerns including DNA damage to pituitary cells from a related compound and a Phase 2 trial death. Dr. Daniela Verthelyi, of the Office of Pharmaceutical Quality, called immunogenicity the "through-line concern": even picogram-level impurities in injectable peptides can trigger cross-reactive antibody responses. Dr. Omer Awan, writing in Forbes this week, also flagged potential ties between committee members and the peptide industry.

2. But the Gray Market Is More Dangerous (Alliance for Pharmacy Compounding, Dr. Abid Husain)

The ban didn't stop use — it pushed patients toward a less safe option.

The gray market already exists and it's largely unregulated. Telegram communities with 35,000 members crowdsource third-party lab testing of peptides from online vendors — because that's what patients do when they can't get a prescription. Dr. Abid Husain, a triple-board-certified physician specializing in peptide therapy, put it plainly: "Right now, most people can't get these compounds in a safe, controlled manner, so they get them however they can."

A formal compounding pathway would add real safeguards. If the committee votes yes, licensed pharmacies would need to prepare these compounds under sterile pharmacy standards with physician oversight. Licensed pharmacies set a higher bar than anything gray market vendors currently offer.

83% of peptide-familiar Americans want the legal route. A Hone Health survey of 2,491 adults conducted in May 2026 found 83% support FDA-approved compounding pharmacy access; 90% said physician involvement would increase their trust. The Alliance for Pharmacy Compounding, which forced this hearing through the courts, argued that "'Trust us' is not a sufficient explanation for agency actions" — meaning FDA has to make its case publicly, not by fiat.

3. The Ban Backfired (HHS Secretary RFK Jr., Andrew Huberman)

RFK Jr. says the FDA's 2023 restrictions were illegal — and the resulting gray market is the proof.

The 2023 restrictions made the gray market worse, not better. As HHS Secretary, RFK Jr. oversees the FDA — and on the Joe Rogan Experience in February 2026, he said the Category 2 designations "created and accelerated the very gray market they were designed to prevent." He's called the restrictions "illegal" and said he expects about 14 of 19 restricted peptides to regain compounding access. As of today, the FDA hasn't published a formal updated list.

These compounds have a real-world track record that animal studies support. Andrew Huberman, a Stanford neuroscientist and podcast host, has spoken positively about BPC-157 for his own spinal injury — while acknowledging "there are essentially no clinical trials and that the risks are real."

No company will fund the trials the FDA demands for unpatentable compounds. Functional medicine physician Dr. Max MacCloud says these compounds represent "functional medicine for age reversal that Big Pharma can't easily patent or control" — and without a commercial pathway, the clinical trials the FDA requires won't get funded.

Where This Lands

The FDA's scientists have the numbers: no controlled human trials, a 167-to-11 committee vote against in 2024, and unresolved immunogenicity concerns. The compounders have a legal win: FDA is now required to make its case publicly rather than restrict by internal guidance. And HHS Secretary RFK Jr., who oversees the FDA, has already called the 2023 restrictions illegal. The PCAC votes Thursday and Friday; whatever it recommends, the FDA still makes the final call.

Sources